Annika Dalheim
Loyola University Chicago
11 Papers
3 Citations
Annika Dalheim is an academic researcher from Loyola University Chicago. The author has contributed to research in topics: T cell & Medicine. The author has an hindex of 4, co-authored 7 publications. Previous affiliations of Annika Dalheim include Uppsala University.
Chat about Author
Papers
Potassium channel activity controls breast cancer metastasis by affecting β-catenin signaling
Eun Kyoung Breuer,Daniela Fukushiro-Lopes,Annika Dalheim,Miranda Burnette,Jeremiah J. Zartman,Simon Kaja,Simon Kaja,Claire M. Wells,Loredana Campo,Kimberly J. Curtis,Ricardo Romero-Moreno,Laurie E. Littlepage,Glen L. Niebur,Kent Hoskins,Michael I. Nishimura,Saverio Gentile,Saverio Gentile +16 more
TL;DR: These findings suggest that Kv11.1 activators may represent a novel therapeutic approach for the treatment of metastatic estrogen receptor-negative BC and provide important information regarding the clinical relevance of potassium ion channel expression in breast tumors and the mechanisms by which potassium channel activity can modulate tumor biology.
Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival.
Fang Wang,Thomas Bank,Gregory Malnassy,Maribel Arteaga,Na Shang,Annika Dalheim,Xianzhong Ding,Scott J. Cotler,Mitchell F. Denning,Michael I. Nishimura,Peter Breslin,Wei Qiu +11 more
- 01 Jun 2018
TL;DR: This study found that insulin‐like growth factor 1 receptor (IGF1R) remains activated in HCC cells treated with sorafenib and found that ceritinib, a drug approved by the U.S. Food and Drug Administration for treatment of non‐small cell lung cancer, effectively inhibits the IGF1R/AKT pathway and enhances the inhibitory efficacy of sorAFenib.
Endothelin-1-Mediated Drug Resistance in EGFR -Mutant Non-Small Cell Lung Carcinoma.
Ines Pulido,Stephen L. Ollosi,Salvador Aparisi,Jeffrey H. Becker,Alicia Aliena-Valero,Marta Benet,Maria L. Rodriguez,Adrián López,Eva Tamayo-Torres,Lourdes Chuliá-Peris,Juan Carlos García-Cañaveras,Margaret Soucheray,Annika Dalheim,Juan B. Salom,Wei Qiu,Simon Kaja,Javier Alcácer Fernández-Coronado,Sandra Alandes,Javier Alcácer,Fatima Al-Shahrour,Jeffrey A. Borgia,Oscar Juan,Michael I. Nishimura,Agustín Lahoz,Julian Carretero,Takeshi Shimamura +25 more
TL;DR: A simplistic endogenous yet previously unrealized resistance mechanism inherent to a subset of EGFR-mutant NSCLC to attenuate tyrosine kinase inhibitor delivery to the tumors by limiting drug-carrying blood flow and the drug concentration in tumors is described.
13
Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response.
TL;DR: In this paper, the authors demonstrate efficient T cell transduction with the melanoma-reactive TIL1383I TCR through culturing with interleukin 7 (IL-7) in the absence of CD3 activation.
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells.
Tamson V. Moore,Gina Scurti,Matthew DeJong,Siao Yi Wang,Annika Dalheim,Courtney Regan Wagner,Kelli A. Hutchens,Jodi Speiser,Constantine Godellas,Chris Fountain,Jessica Fleser,Tarsem Moudgil,Mallory Thomas,David C. Murray,Brendan D. Curti,Joseph I. Clark,Bernard A. Fox,Bernard A. Fox,Michael I. Nishimura +18 more
TL;DR: In this article, a clinical trial was conducted on seven metastatic melanoma patients with autologous T-cells transduced to express a tyrosinase-reactive T-cell receptor (TCR) (TIL 1383I) and truncated CD34 molecule as a selection marker.
7